ProCE Banner Activity

BCMA-Targeting Agents in Relapsed/Refractory Multiple Myeloma: Current Approved Indications and General Management of Toxicities


Download this resource for useful point-of-care information including current approvals, clinical trial data, and AE identification and management with BCMA-targeting agents.

Released: June 23, 2023



Suzanne Lentzsch

Suzanne Lentzsch, MD, PhD

Professor of Medicine
Division of Hematology/Oncology
Columbia University Medical Center
New York, New York

Sagar Lonial

Sagar Lonial, MD, FACP

Professor and Chair
Department of Hematology and Medical Oncology
Emory University
Atlanta, Georgia

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner


Supported by educational grants from Bristol Myers Squibb and Regeneron Pharmaceuticals, Inc.

Bristol Myers Squibb

Regeneron Pharmaceuticals, Inc